JP6792553B2 - 腎障害および腎不全の診断および予後のための方法および組成物 - Google Patents

腎障害および腎不全の診断および予後のための方法および組成物 Download PDF

Info

Publication number
JP6792553B2
JP6792553B2 JP2017521231A JP2017521231A JP6792553B2 JP 6792553 B2 JP6792553 B2 JP 6792553B2 JP 2017521231 A JP2017521231 A JP 2017521231A JP 2017521231 A JP2017521231 A JP 2017521231A JP 6792553 B2 JP6792553 B2 JP 6792553B2
Authority
JP
Japan
Prior art keywords
hours
serum creatinine
subject
renal
urine volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017521231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533427A (ja
JP2017533427A5 (enExample
Inventor
アンダーバーグ，ジョセフ
マクファーソン，ポール
グレイ，ジェフ
ナカムラ，ケビン
カンプフ，ジェームズ，パトリック
クワン，トーマス
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2017533427A publication Critical patent/JP2017533427A/ja
Publication of JP2017533427A5 publication Critical patent/JP2017533427A5/ja
Application granted granted Critical
Publication of JP6792553B2 publication Critical patent/JP6792553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2017521231A 2014-10-20 2015-10-20 腎障害および腎不全の診断および予後のための方法および組成物 Active JP6792553B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462066316P 2014-10-20 2014-10-20
US201462066313P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
US62/066,310 2014-10-20
US62/066,313 2014-10-20
US62/066,316 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020185705A Division JP7002623B2 (ja) 2014-10-20 2020-11-06 腎障害および腎不全の診断および予後のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017533427A JP2017533427A (ja) 2017-11-09
JP2017533427A5 JP2017533427A5 (enExample) 2019-01-10
JP6792553B2 true JP6792553B2 (ja) 2020-11-25

Family

ID=55761743

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521231A Active JP6792553B2 (ja) 2014-10-20 2015-10-20 腎障害および腎不全の診断および予後のための方法および組成物
JP2020185705A Active JP7002623B2 (ja) 2014-10-20 2020-11-06 腎障害および腎不全の診断および予後のための方法および組成物
JP2021211779A Active JP7217796B2 (ja) 2014-10-20 2021-12-27 腎障害および腎不全の診断および予後のための方法および組成物
JP2023008480A Pending JP2023052587A (ja) 2014-10-20 2023-01-24 腎障害および腎不全の診断および予後のための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020185705A Active JP7002623B2 (ja) 2014-10-20 2020-11-06 腎障害および腎不全の診断および予後のための方法および組成物
JP2021211779A Active JP7217796B2 (ja) 2014-10-20 2021-12-27 腎障害および腎不全の診断および予後のための方法および組成物
JP2023008480A Pending JP2023052587A (ja) 2014-10-20 2023-01-24 腎障害および腎不全の診断および予後のための方法および組成物

Country Status (13)

Country Link
US (2) US11333671B2 (enExample)
EP (2) EP3968022A1 (enExample)
JP (4) JP6792553B2 (enExample)
KR (1) KR102431003B1 (enExample)
CN (2) CN107003301B (enExample)
AU (2) AU2015336069B2 (enExample)
BR (1) BR112017008218A2 (enExample)
CA (1) CA2965153C (enExample)
EA (1) EA201790696A1 (enExample)
ES (1) ES2907551T3 (enExample)
MX (1) MX388231B (enExample)
PT (1) PT3210018T (enExample)
WO (1) WO2016064877A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388231B (es) 2014-10-20 2025-03-19 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.
EP4063853A1 (en) * 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
AU2019249070B2 (en) * 2018-04-02 2024-06-13 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
US20220236285A1 (en) * 2019-05-24 2022-07-28 Astute Medical, Inc. Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
AU2021381364A1 (en) * 2020-11-18 2023-06-22 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20030157573A1 (en) 2002-02-12 2003-08-21 Orna Mor Use of Axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
AU2009223784A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
CN104020284B (zh) * 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2462443A4 (en) * 2009-08-07 2013-01-30 Rules Based Medicine Inc METHODS AND DEVICES FOR DETECTING GLOMERULONEPHRITH AND ASSOCIATED DISORDERS
NZ599105A (en) * 2009-09-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290192A1 (ru) * 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2012005210A (es) * 2009-11-07 2012-08-03 Astute Medical Inc Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK2666872T3 (en) * 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
WO2011162821A1 (en) * 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103080743B (zh) 2010-06-23 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9410968B2 (en) 2011-04-04 2016-08-09 Universiteit Gent Biomarkers for acute kidney injury
ES2721907T3 (es) * 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013096740A1 (en) 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
US20160003850A1 (en) 2013-02-26 2016-01-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX388231B (es) 2014-10-20 2025-03-19 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Also Published As

Publication number Publication date
BR112017008218A2 (pt) 2018-01-09
US12099067B2 (en) 2024-09-24
CA2965153C (en) 2023-10-24
EP3210018A2 (en) 2017-08-30
US20220236286A1 (en) 2022-07-28
CN110702921A (zh) 2020-01-17
WO2016064877A3 (en) 2016-09-09
AU2015336069A1 (en) 2017-05-25
EP3968022A1 (en) 2022-03-16
JP2017533427A (ja) 2017-11-09
JP7002623B2 (ja) 2022-02-10
ES2907551T3 (es) 2022-04-25
EP3210018A4 (en) 2018-06-20
JP2023052587A (ja) 2023-04-11
CN107003301B (zh) 2019-11-01
JP2022046669A (ja) 2022-03-23
US11333671B2 (en) 2022-05-17
CN110702921B (zh) 2024-02-06
PT3210018T (pt) 2021-10-04
EP3210018B1 (en) 2021-07-28
JP7217796B2 (ja) 2023-02-03
CA2965153A1 (en) 2016-04-28
EA201790696A1 (ru) 2017-10-31
AU2022201130A1 (en) 2022-03-17
MX2017005126A (es) 2017-09-15
WO2016064877A2 (en) 2016-04-28
CN107003301A (zh) 2017-08-01
JP2021039112A (ja) 2021-03-11
US20180209990A1 (en) 2018-07-26
KR102431003B1 (ko) 2022-08-09
AU2015336069B2 (en) 2021-11-25
AU2022201130B2 (en) 2024-06-27
KR20170084102A (ko) 2017-07-19
MX388231B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
JP7002623B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
JP5947544B2 (ja) 腎損傷および腎不全の診断および予後のための方法および組成物
JP5735922B2 (ja) 腎損傷および腎不全の診断および予後のための方法
JP5827226B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
RS54879B1 (sr) Metode i kompozicije za dijagnoze i prognoze oštećenja bubrega i bubrežne insuficijencije
KR20140074307A (ko) 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물
HK1200218A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1220764A1 (zh) 肾损伤和肾衰竭的诊断及预後
JP2017534874A (ja) 腎損傷および腎不全の診断および予後のための方法および組成物。
JP6538353B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
HK1207155A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2018521307A (ja) 腎障害および腎不全の診断および予後のための方法および組成物
JP2018518676A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
HK1236620A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1236621A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1212774B (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
HK1219129A1 (zh) 用於肾损伤和肾衰竭的诊断及预後的方法和组合物
HK1212774A1 (zh) 用於腎損傷和腎衰竭的診斷及預後方法和組合物
HK1203620B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1162617B (zh) 腎損傷和腎衰竭的診斷和預後
HK1195128A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1195128B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1195127A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1167889B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1171261B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201106

R150 Certificate of patent or registration of utility model

Ref document number: 6792553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250